Rebecca Taub A.'s most recent trade in Madrigal Pharmaceuticals Inc was a trade of 43,263 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Aug. 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 43,263 | 0 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 11 Aug 2025 | 43,263 | 504,307 (3%) | 0% | 9.4 | 408,835 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 357.85 per share. | 11 Aug 2025 | 6,715 | 468,285 (3%) | 0% | 357.9 | 2,402,982 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 358.81 per share. | 11 Aug 2025 | 6,541 | 461,744 (2%) | 0% | 358.8 | 2,346,983 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 354.97 per share. | 11 Aug 2025 | 6,479 | 485,616 (3%) | 0% | 355.0 | 2,299,873 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 355.95 per share. | 11 Aug 2025 | 5,752 | 479,864 (3%) | 0% | 356.0 | 2,047,436 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 356.88 per share. | 11 Aug 2025 | 4,864 | 475,000 (3%) | 0% | 356.9 | 1,735,861 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 354.04 per share. | 11 Aug 2025 | 4,587 | 492,095 (3%) | 0% | 354.0 | 1,623,997 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 350.87 per share. | 11 Aug 2025 | 3,580 | 500,727 (3%) | 0% | 350.9 | 1,256,127 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 3,200 | 43,263 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 11 Aug 2025 | 3,200 | 464,244 (3%) | 0% | 9.5 | 30,240 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 350.18 per share. | 11 Aug 2025 | 2,980 | 461,264 (2%) | 0% | 350.2 | 1,043,528 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 351.60 per share. | 11 Aug 2025 | 2,870 | 497,857 (3%) | 0% | 351.6 | 1,009,091 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 352.45 per share. | 11 Aug 2025 | 1,175 | 496,682 (3%) | 0% | 352.5 | 414,130 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 359.71 per share. | 11 Aug 2025 | 700 | 461,044 (2%) | 0% | 359.7 | 251,798 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 351.02 per share. | 11 Aug 2025 | 220 | 461,044 (2%) | 0% | 351.0 | 77,225 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 350.00 per share. | 18 Jul 2025 | 1,000 | 461,044 (2%) | 0% | 350.0 | 350,005 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 18 Jul 2025 | 1,000 | 462,044 (2%) | 0% | 9.5 | 9,450 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jul 2025 | 1,000 | 46,463 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2025 | 26,444 | 50,120 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 16 Jul 2025 | 26,444 | 487,488 (3%) | 0% | 9.5 | 249,896 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 355.61 per share. | 16 Jul 2025 | 6,441 | 462,424 (2%) | 0% | 355.6 | 2,290,499 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 350.19 per share. | 16 Jul 2025 | 6,000 | 481,488 (3%) | 0% | 350.2 | 2,101,142 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 354.61 per share. | 16 Jul 2025 | 5,800 | 468,865 (3%) | 0% | 354.6 | 2,056,738 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2025 | 2,657 | 47,463 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 16 Jul 2025 | 2,657 | 463,701 (3%) | 0% | 9.5 | 25,109 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 353.82 per share. | 16 Jul 2025 | 2,569 | 474,665 (3%) | 0% | 353.8 | 908,963 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 352.64 per share. | 16 Jul 2025 | 2,357 | 477,234 (3%) | 0% | 352.6 | 831,170 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 350.09 per share. | 16 Jul 2025 | 2,057 | 461,644 (2%) | 0% | 350.1 | 720,137 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 351.37 per share. | 16 Jul 2025 | 1,897 | 479,591 (3%) | 0% | 351.4 | 666,546 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 356.52 per share. | 16 Jul 2025 | 1,380 | 461,044 (2%) | 0% | 356.5 | 492,004 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director | Sale of securities on an exchange or to another person at price $ 351.50 per share. | 16 Jul 2025 | 600 | 461,044 (2%) | 0% | 351.5 | 210,898 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 7,381 | 7,381 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 4,382 | 461,044 (2%) | 0% | 0 | Common Stock | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 335.24 per share. | 24 Jan 2025 | 648 | 456,662 (2%) | 0% | 335.2 | 217,236 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 273.41 per share. | 17 Jan 2025 | 1,689 | 457,310 (2%) | 0% | 273.4 | 461,789 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 08 Apr 2024 | 2,676 | 461,675 (2%) | 0% | 9.4 | 25,288 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2024 | 2,676 | 76,564 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 244.79 per share. | 08 Apr 2024 | 945 | 460,506 (2%) | 0% | 244.8 | 231,325 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 246.98 per share. | 08 Apr 2024 | 600 | 459,606 (2%) | 0% | 247.0 | 148,186 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 247.76 per share. | 08 Apr 2024 | 407 | 459,199 (2%) | 0% | 247.8 | 100,838 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 245.69 per share. | 08 Apr 2024 | 300 | 460,206 (2%) | 0% | 245.7 | 73,706 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 243.25 per share. | 08 Apr 2024 | 224 | 461,451 (2%) | 0% | 243.2 | 54,487 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 248.58 per share. | 08 Apr 2024 | 200 | 458,999 (2%) | 0% | 248.6 | 49,716 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 27,845 | 125,283 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 03 Apr 2024 | 27,845 | 486,844 (3%) | 0% | 9.4 | 263,135 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 27,506 | 79,240 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 03 Apr 2024 | 27,506 | 486,505 (3%) | 0% | 9.5 | 259,932 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 245.34 per share. | 03 Apr 2024 | 18,917 | 461,088 (2%) | 0% | 245.3 | 4,641,014 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 18,537 | 106,746 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 03 Apr 2024 | 18,537 | 477,536 (3%) | 0% | 9.5 | 175,175 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 243.33 per share. | 03 Apr 2024 | 8,989 | 466,356 (3%) | 0% | 243.3 | 2,187,288 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 242.61 per share. | 03 Apr 2024 | 8,817 | 475,345 (3%) | 0% | 242.6 | 2,139,069 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 241.85 per share. | 03 Apr 2024 | 5,619 | 467,717 (3%) | 0% | 241.9 | 1,358,971 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 245.53 per share. | 03 Apr 2024 | 5,278 | 458,999 (2%) | 0% | 245.5 | 1,295,924 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 240.88 per share. | 03 Apr 2024 | 4,200 | 473,336 (3%) | 0% | 240.9 | 1,011,679 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 244.68 per share. | 03 Apr 2024 | 4,070 | 480,005 (3%) | 0% | 244.7 | 995,854 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 242.71 per share. | 03 Apr 2024 | 3,085 | 464,632 (3%) | 0% | 242.7 | 748,765 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 245.06 per share. | 03 Apr 2024 | 2,734 | 461,463 (2%) | 0% | 245.1 | 670,006 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 243.68 per share. | 03 Apr 2024 | 2,634 | 484,075 (3%) | 0% | 243.7 | 641,866 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 246.33 per share. | 03 Apr 2024 | 2,089 | 458,999 (2%) | 0% | 246.3 | 514,573 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 244.45 per share. | 03 Apr 2024 | 2,079 | 464,277 (3%) | 0% | 244.5 | 508,213 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 246.01 per share. | 03 Apr 2024 | 1,653 | 459,810 (2%) | 0% | 246.0 | 406,658 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 240.11 per share. | 03 Apr 2024 | 1,643 | 484,862 (3%) | 0% | 240.1 | 394,497 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 247.23 per share. | 03 Apr 2024 | 711 | 459,099 (2%) | 0% | 247.2 | 175,778 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 241.14 per share. | 03 Apr 2024 | 700 | 484,162 (3%) | 0% | 241.1 | 168,799 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 244.01 per share. | 03 Apr 2024 | 435 | 464,197 (3%) | 0% | 244.0 | 106,143 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 242.00 per share. | 03 Apr 2024 | 135 | 486,709 (3%) | 0% | 242 | 32,670 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 248.23 per share. | 03 Apr 2024 | 100 | 458,999 (2%) | 0% | 248.2 | 24,823 | Common Stock |
| Madrigal Pharmaceuticals Inc | Taub Rebecca A. | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 8,718 | 8,718 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca Taub A. | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 5,786 | 5,786 | - | - | Market Stock Unit | |
| Madrigal Pharmaceuticals Inc | Rebecca Taub A. | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 5,786 | 20,787 (0%) | 0% | 0 | Common Stock | |
| Madrigal Pharmaceuticals Inc | Rebecca Taub A. | Director, Pres., R&D, and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.92 per share. | 16 Jan 2024 | 1,546 | 15,001 (0%) | 0% | 243.9 | 377,100 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 20,001 | 20,001 (0%) | 0% | 0 | Common Stock | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 61,500 | 61,500 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) |